1-(2-萘基甲基)哌嗪 | 61187-16-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(2-萘基甲基)哌嗪
• 英文名称: 1-(β-naphthylmethyl)piperazine
• 英文别名: 1-(naphthalen-2-ylmethyl)piperazine；1-(2-naphthylmethyl)-piperazine；1-[2]naphthylmethyl-piperazine；1-[2]Naphthylmethyl-piperazin；1-(β-napthylmethyl)piperazine
• CAS: 61187-16-4
• 化学式: C₁₅H₁₈N₂
• mdl: MFCD00435480
• 分子量: 226.321
• InChiKey: FDVCUOJHWRHXMF-UHFFFAOYSA-N

物化性质

• 沸点：
  155-160 °C(Press: 1 Torr)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(2-萘基甲基)哌嗪 在 盐酸 、 碳酸氢钠 、 肼 作用下， 以 乙二醇乙醚 、 乙醇 、 水 、 丙酮 为溶剂， 生成 N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)-2-(4-(naphthalen-2-ylmethyl)piperazin-1-yl)acetohydrazide
  参考文献：
  名称：

  Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)

  摘要：

  Procaspase-Activating Compound 1 (PAC-1) is an ortho-hydroxy N-acyl hydrazone that enhances the enzymatic activity of procaspase-3 in vitro and induces apoptosis in cancer cells. An analogue of PAC-1, called S-PAC-1, was evaluated in a veterinary clinical trial in pet dogs with lymphoma and found to have considerable potential as an anticancer agent. With the goal of identifying more potent compounds in this promising class of experimental therapeutics, a combinatorial library based on PAC-1 was created, and the compounds were evaluated for their ability to induce death of cancer cells in culture. For library construction, 31 hydrazides were condensed in parallel with 27 aldehydes to create 837 PAC-1 analogues, with an average purity of 91%. The compounds were evaluated for their ability to induce apoptosis in cancer cells, and through this work, six compounds were discovered to be substantially more potent than PAC-1 and S-PAC-1. These six hits were further evaluated for their ability to relieve zinc-mediated inhibition of procaspase-3 in vitro. In general, the newly identified hit compounds are two- to four-fold more potent than PAC-1 and S-PAC-1 in cell culture, and thus have promise as experimental therapeutics for treatment of the many cancers that have elevated expression levels of procaspase-3.

  DOI：

  10.1021/co2001372
• 作为产物：
  描述：

  2-(氯甲基)萘 在 sodium hydroxide 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(2-萘基甲基)哌嗪
  参考文献：
  名称：

  Synthesis and structure-activity relationships of novel 2-amino alkyl chromones and related derivatives as a site-selective ligands

  摘要：

  Starling from a random screening showing that 2-[(4-benzylpiperazinyl)methyl] chromone was a selective and potent sigma ligand, a series of analogues were synthesized. Introduction of a substituent on the chromone moiety, replacement of methylenes by carbonyl groups and benzyl by aryl groups decrease the affinity for sigma sites. The result obtained after introduction of various substituents on the aromatic part of the benzyl is strictly depending on the size and on the position of these substituents. Stretching of the carbon chain between the phenyl and the piperazine does not strongly modify the affinity. 2-[4-(4'-methoxy benzyl)-1-piperazinyl methyl] chromone has been tested in behavioral tests that permit to believe that such derivatives could be interesting for the treatment of psychosis. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80001-9

文献信息

• Synthesis of Aza-acyclic Nucleoside Libraries of Purine, Pyrimidine, and 1,2,4-Triazole
  作者：Vibha Pathak、Ashish K. Pathak、Robert C. Reynolds

  DOI：10.1021/acscombsci.8b00136

  日期：2019.3.11

  of the Pilot Scale Library Program of the NIH Roadmap Initiative, a new library of propan-1-amine containing aza acyclic nucleosides was designed and prepared, and we now report a diverse set of 157 purine, pyrimidine, and 1,2,4-triazole-N-acetamide analogues. These new nucleoside analogues were prepared in a parallel high throughput solution-phase format. A set of diverse amines was reacted with several

  在美国国立卫生研究院路线图计划的试点图书馆计划的主持下，设计并制备了一个新的含有丙-1-胺的氮杂无环核苷图书馆，我们现在报告了157种嘌呤，嘧啶和1,2 ，4-三唑-N-乙酰胺类似物。这些新的核苷类似物以平行的高通量溶液相形式制备。一组不同的胺与几个核碱基N反应-丙醛利用与三乙酰氧基硼氢化钠偶合的还原胺化来生成一个小的且多样化的氮杂无环核苷文库。所有反应均在惰性气氛下使用24孔反应模块和自动试剂分配平台进行。使用固体样品上样的预装柱和硅胶柱在自动化系统上纯化最终目标。所有化合物均通过NMR和HRMS进行表征，并通过HPLC分析纯度，然后提交分子库小分子储存库（MLSMR）。通过分子图书馆探针生产中心网络（MLPCN）进行的初步筛选显示了多种有趣的生物学活动。
• Novel compounds and compositions for treating Parkinson's disease
  申请人：SmithKline Corporation

  公开号：US03988457A1

  公开（公告）日：1976-10-26

  .beta.-Naphthylmethyl piperazinyl derivates having anti-Parkinsonism activity prepared by condensation of .beta.-chloromethylnaphthalene with the appropriate substituted piperazine.

  具有抗帕金森病活性的.beta.-萘甲基哌嗪衍生物是通过将.beta.-氯甲基萘与适当取代的哌嗪进行缩合制备的。
• Compounds and methods to treat cardiac failure and other disorders
  申请人：Scios, Inc.

  公开号：US06340685B1

  公开（公告）日：2002-01-22

  A compound of the formula: and the pharmaceutically acceptable salts thereof, wherein each of Z1 and Z2 is independently CR4 or N; where each R4 is independently H or is alkyl (1-6C) optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by CN or ═O, or by an aliphatic or aromatic 5 or 6 membered ring optionally containing 1-2 N heteroatoms; or two R4 taken together form a bridge optionally containing a heteroatom; R1 is  wherein X1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two 6 taken together may form an alkyene (2-3C) bridge; n is 0 or 2; Z3 is CH or N; X2 is CH, CH2 or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X2 optionally substituted by halo, nitro, alkyl (1-6C), alkenyl (1-6C), CN or CF3, or by RCO, COOR, CONR2, NR2, OR, SR, OOCR or NROCR wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the foregoing substituents; R2 is H, or alkyl (1-6C) optionally including one heteroatom which is O, S or N, and optionally substituted by one or more of halo, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by CN or ═O, or by an aliphatic or aromatic 5 or 6 membered ring optionally containing 1-2 N heteroatoms; R3 is H, halo, NO2, alkyl (1-6C), alkenyl (1-6C), CN, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C).

  该化合物的公式为：，以及其中每种Z1和Z2独立为CR4或N；其中每个R4独立为H或为烷基（1-6C），可选地包括一个或多个选自O、S和N的杂原子，并可选地被一个或多个卤素、OR、SR、NR2、RCO、COOR、CONR2、OOCR或NROCR取代，其中R为H或烷基（1-6C），或由CN或═O，或由脂肪族或芳香族5或6元环可选地含有1-2个N杂原子；两个R4一起可形成一个含杂原子的桥；R1是，其中X1是CO或其等立体异构体；m为0或1；Y为可选地取代的烷基，可选地取代的芳基，或可选地取代的芳烷基，或两个6一起可形成一个烯基（2-3C）桥；n为0或2；Z3是CH或N；X2是CH，CH2或其等立体异构体；Ar由一个或两个直接与X2偶联的苯基部分组成，可被卤素、硝基、烷基（1-6C）、烯基（1-6C）、CN或CF3，或由RCO、COOR、CONR2、NR2、OR、SR、OOCR或NROCR取代，其中R为H或烷基（1-6C）或由苯基，其本身可被上述取代基所取代；R2是H，或烷基（1-6C），可选地包括一个杂原子，其为O、S或N，并可选地被一个或多个卤素、OR、SR、NR2、RCO、COOR、CONR2、OOCR或NROCR取代，其中R为H或烷基（1-6C），或由CN或═O，或由脂肪族或芳香族5或6元环可选地含有1-2个N杂原子；R3是H，卤素，NO2，烷基（1-6C），烯基（1-6C），CN，OR，SR，NR2，RCO，COOR，CONR2，OOCR，或NROCR，其中R是H或烷基（1-6C）。
• SUBSTITUTED ISOQUINOLINE DERIVATIVE
  申请人：Hidaka Hiroyoshi

  公开号：US20120035159A1

  公开（公告）日：2012-02-09

  The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH═CH, O, or S; R 1 and R 2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R 3 and R 4 each independently represent a hydrogen atom, an alkyl group, or the like, or R 3 and R 4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.

  本发明提供了一种作为新型药物剂的异喹啉-6-磺酰胺衍生物。本发明提供了由式（1）表示的异喹啉-6-磺酰胺衍生物，其盐或该衍生物或盐的溶剂：其中X和Y分别独立表示直接键，NH，CH═CH，O或S；R1和R2分别独立表示氢原子，卤素原子，氰基，烷基或类似物；R3和R4分别独立表示氢原子，烷基或类似物，或R3和R4共同形成烷基或烯基，可以在两个碳原子之间被桥接到任意位置；l，m和n表示1到4的整数。
• Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α₂-Adrenoceptor Blocking Activity
  作者：J. Ignacio Andrés、Jesús Alcázar、José M. Alonso、Rosa M. Alvarez、Margot H. Bakker、Ilse Biesmans、José M. Cid、Ana I. De Lucas、Javier Fernández、Luis M. Font、Koen A. Hens、Laura Iturrino、Ilse Lenaerts、Sonia Martínez、Anton A. Megens、Joaquín Pastor、Patrick C. M. Vermote、Thomas Steckler

  DOI：10.1021/jm049619s

  日期：2005.3.1

  The synthesis and pharmacology of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptake inhibition with alpha(2)-adrenoceptor blocking activity is described as potential antidepressants. Four compounds were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly

  一系列新的3-哌嗪基甲基-3a，4-二氢-3H- [1]苯并吡喃并[4,3-c]异恶唑的合成和药理作用，结合了中央5-羟色胺（5-HT）再摄取抑制与α（2）-肾上腺素受体阻断活性被描述为潜在的抗抑郁药。选择了四种化合物进行进一步评估，发现这两种活性的组合是立体选择性的，主要存在于一种对映异构体中。在大鼠中由α（2）-激动剂美托咪定诱导的扶正丧失的逆转证实了体内的α（2）-肾上腺素受体阻断活性，并且还证明了CNS的渗透。对氯苯丙胺（pCA）诱导的兴奋性的拮抗作用以及对p-CA给药引起的神经元5-HT消耗的阻滞证实，即使在口服后，它们也具有阻断中枢5-HTT的能力。